<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2024-633-639</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3660</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Оценка лабораторных показателей воспаления, инфекции и признаков субклинического атеросклероза у больных системной красной волчанкой</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of laboratory indicators of inflammatory, infection and indicators of subclinical atherosclerosis in patients with systemic lupus erythematosus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0297-8163</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аршинов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Arshinov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аршинов Андрей Владимирович </p><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>Andrey V. Arshinov </p><p>150000, Yaroslavl, Revolyutsionnaya str., 5</p></bio><email xlink:type="simple">a_arshinov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4846-4931</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левшин</surname><given-names>Н. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Levshin</surname><given-names>N. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>Nikolay Yu. Levshin </p><p>150000, Yaroslavl, Revolyutsionnaya str., 5</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2781-814X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маслова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Maslova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>Irina G. Maslova </p><p>150000, Yaroslavl, Revolyutsionnaya str., 5</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7847-1679</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>Andrey A. Baranov </p><p>150000, Yaroslavl, Revolyutsionnaya str., 5</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5716-3423</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Емануйлов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Emanuylov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>Vladislav I. Emanuylov </p><p>150000, Yaroslavl, Revolyutsionnaya str., 5</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yaroslavl State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><volume>62</volume><issue>6</issue><fpage>633</fpage><lpage>639</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аршинов А.В., Левшин Н.Ю., Маслова И.Г., Баранов А.А., Емануйлов В.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Аршинов А.В., Левшин Н.Ю., Маслова И.Г., Баранов А.А., Емануйлов В.И.</copyright-holder><copyright-holder xml:lang="en">Arshinov A.V., Levshin N.Y., Maslova I.G., Baranov A.A., Emanuylov V.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3660">https://rsp.mediar-press.net/rsp/article/view/3660</self-uri><abstract><p>Цель исследования – выявить взаимосвязь между активностью воспаления, инфекцией, функцией тромбоцитов и дислипидемией в развитии субклинического атеросклероза у пациентов с системной красной волчанкой (СКВ).</p><sec><title>Материал и методы</title><p>Материал и методы. Обследовано 50 женщин с СКВ, медиана возраста – 52,0 [48,0–58,0] года, медиана длительности заболевания – 11,5 [6,0–22,0] лет. Контрольную группу составила 21 здоровая женщина. Концентрацию С-реактивного белка (СРБ), интерлейкина 6 (ИЛ-6), IgG антител к Chlamydia pneumonia (АCP), Толл-подобного рецептора (TLR, Toll like receptor) 2, тромбоцитарного фактора 4 (ТФ4) и антител к окисленным липопротеинам низкой плотности (АОЛПНП) определяли иммуноферментным методом. Исследовали показатели агрегации тромбоцитов, липидного спектра, толщину комплекса интима – медиа (ТКИМ) общих сонных артерий.</p></sec><sec><title>Результаты</title><p>Результаты. У больных СКВ по сравнению c контролем выявлено значительное увеличение ТКИМ общей сонной артерии (медиана – 1,00 [0,80–1,10] и 0,80 [0,70–0,90] мм соответственно; p&lt;0,01) и ТКИМ бифуркации сонной артерии (1,10 [1,00–1,20] и 0,80 [0,70–1,10] мм соответственно; p&lt;0,01), повышение концентрации СРБ (3,67 [2,17–5,92] и 0,74 [0,30–1,26] мг/л соответственно; p&lt;0,01), ИЛ-6 (1,72 [1,39–2,68] и 0,60 [0,22–0,75] пг/мл соответственно; p&lt;0,01). При СКВ отмечена значительная активация тромбоцитов со статистически значимым увеличением концентрации ТФ4 (медиана – 21,5 [19,80–23,28] и 18,30 [13,88– 20,46] нг/мл соответственно; p&lt;0,01), выраженная дислипидемия, повышение концентрации АОЛПНП (3,16 [1,45–4,60] и 1,39 [1,26–2,04] МЕ/мл соответственно; p&lt;0,01). Концентрация АCP и TLR2 у пациентов с СКВ и в контроле не различалась.</p></sec><sec><title>Заключение</title><p>Заключение. Ассоциация между СКВ и субклиническим атеросклеротическим поражением сосудистой стенки, помимо традиционных факторов риска развития сердечно-сосудистых заболеваний, может быть связана с дополнительными факторами риска – воспалением и аутоиммунными процессами. Роль инфекции подлежит дальнейшему изучению.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to reveal the relationship between the activity of inflammation, the infectious component, platelet function and dyslipidemia, in the development of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).</p><sec><title>Material and methods</title><p>Material and methods. Fifty women with SLE at the age of 52.0 [48.0–58.0] years and disease duration – 11.5 [6.0– 22.0] years were examined. The control group consisted of 21 healthy women. The concentration of high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), IgG antibodies to Chlamydia pneumonia (at IgG CP), the level of Toll-like receptor (TLR2), platelet factor 4 (PF4) and antibodies to oxidized high-density lipoproteins (at oxLDL) were determined by enzyme immunoassay. Platelet aggregation indices, lipid spectrum, intima-media thickness (IMT) of common carotid arteries were investigated.</p></sec><sec><title>Results</title><p>Results. A significant increase in IMT of the common carotid artery (1.00 [0.80–1.10] and 0.80 [0.70–0.90] mm, respectively; p&lt;0.01) and TKIM of the carotid bifurcation (1.10 [1.00–1.20] and 0.80 [0.70–1.10] mm, respectively; p&lt;0.01), increased hsCRP concentration (3.67 [2.17–5.92] and 0.74 [0.30–1.26] mg/L, respectively; p&lt;0.01), IL-6 (1.72 [1.39–2.68] and 0.60 [0.22–0.75] pg/mL, respectively; p&lt;0.01). Significant platelet activation was noted in SLE: significant increase in TF4 concentration (21.5 [19.80–23.28] and 18.30 [13.88–20.46] ng/mL, respectively; p&lt;0.01), marked dyslipidemia, increased concentration of oxLDL (3.16 [1.45–4.60] and 1.39 [1.26–2.04] kp, respectively; p&lt;0.01). At IgG CP concentration and TLR2 values in patients with SLE did not differ from controls.</p></sec><sec><title>Conclusion</title><p>Conclusion. In addition to traditional risk factors for the development of cardiovascular disease, the association between SLE and subclinical atherosclerotic lesions of the vascular wall can be explained by additional risk factors – inflammation and autoimmune processes. The role of the infectious component is for further study.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>воспаление</kwd><kwd>тромбоциты</kwd><kwd>Chlamydia pneumonia</kwd><kwd>TLR2</kwd><kwd>атеросклероз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>inflammation</kwd><kwd>platelets</kwd><kwd>chlamydia pneumonia</kwd><kwd>TLR2</kwd><kwd>atherosclerosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi:10.47360/1995-4484-2021-119-128</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi:10.47360/1995-4484-2021-119-128</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and diseaserelated risk factors reported by the EULAR recommendations. RMD Open. 2023;9(1):e002767. doi: 10.1136/rmdopen-2022-002767</mixed-citation><mixed-citation xml:lang="en">Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and diseaserelated risk factors reported by the EULAR recommendations. RMD Open. 2023;9(1):e002767. doi: 10.1136/rmdopen-2022-002767</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733</mixed-citation><mixed-citation xml:lang="en">Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guzmán-Martínez G, Marañón C. Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. Front Immunol. 2022;(13):974826. doi: 10.3389/fimmu.2022.974826</mixed-citation><mixed-citation xml:lang="en">Guzmán-Martínez G, Marañón C. Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. Front Immunol. 2022;(13):974826. doi: 10.3389/fimmu.2022.974826</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Reiss AB, Jacob B, Ahmed S, Carsons SE, DeLeon J. Understanding accelerated atherosclerosis in systemic lupus erythematosus: Toward better treatment and prevention. Inflammation. 2021;44(5):1663-1682. doi: 10.1007/s10753-021-01455-6</mixed-citation><mixed-citation xml:lang="en">Reiss AB, Jacob B, Ahmed S, Carsons SE, DeLeon J. Understanding accelerated atherosclerosis in systemic lupus erythematosus: Toward better treatment and prevention. Inflammation. 2021;44(5):1663-1682. doi: 10.1007/s10753-021-01455-6</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: A systematic review and meta-analysis. RMD Open. 2020;6(2):e001247. doi: 10.1136/rmdopen-2020-001247</mixed-citation><mixed-citation xml:lang="en">Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: A systematic review and meta-analysis. RMD Open. 2020;6(2):e001247. doi: 10.1136/rmdopen-2020-001247</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gerasimova EV, Popkova TV, Gerasimova DA, Kirichenko TV. Macrophage dysfunction in autoimmune rheumatic diseases and atherosclerosis. Int J Mol Sci. 2022;23(9):4513. doi: 10.3390/ijms23094513</mixed-citation><mixed-citation xml:lang="en">Gerasimova EV, Popkova TV, Gerasimova DA, Kirichenko TV. Macrophage dysfunction in autoimmune rheumatic diseases and atherosclerosis. Int J Mol Sci. 2022;23(9):4513. doi: 10.3390/ijms23094513</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Насонова ВА. Системная красная волчанка. М.: Медицина; 972.</mixed-citation><mixed-citation xml:lang="en">Насонова ВА. Системная красная волчанка. М.:Медицина; 972. [Nasonova VA. Systemic lupus erythematosus. Moscow: Meditsina;1972 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Асеева ЕА, Соловьев СК, Насонов ЕЛ. Современные методы оценки активности системной красной волчанки. Научно-практическая ревматология. 2013;2(51):186-200. doi: 10.14412/1995-4484-2013-648</mixed-citation><mixed-citation xml:lang="en">Aseeva EA, Solovyev SK, Nasonov EL. Current methods for evaluating the activity of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(2): 186-200 (In Russ.). doi: 10.14412/1995-4484-2013-648</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al. Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(8):917-933. doi: 10.1016/j.echo.2020.04.021</mixed-citation><mixed-citation xml:lang="en">Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al. Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(8):917-933. doi: 10.1016/j.echo.2020.04.021</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C, Li T, Zhu X, Yuan Y, Wang Y. Haemoglobin A1c variability is independently associated with carotid intima media thickness and plaque in type 2 diabetes: A retrospective, crosssectional study. Endocr J. 2023;70(9):891-900. doi: 10.1507/endocrj.EJ23-0134</mixed-citation><mixed-citation xml:lang="en">Chen C, Li T, Zhu X, Yuan Y, Wang Y. Haemoglobin A1c variability is independently associated with carotid intima media thickness and plaque in type 2 diabetes: A retrospective, crosssectional study. Endocr J. 2023;70(9):891-900. doi: 10.1507/endocrj.EJ23-0134</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">López P, Rodríguez-Carrio J, Martínez-Zapico A, Pérez-Álvarez ÁI, Suárez-Díaz S, Mozo L, et al. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology (Oxford). 2020;59(7):1752- 1764. doi: 10.1093/rheumatology/keaa016</mixed-citation><mixed-citation xml:lang="en">López P, Rodríguez-Carrio J, Martínez-Zapico A, Pérez-Álvarez ÁI, Suárez-Díaz S, Mozo L, et al. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology (Oxford). 2020;59(7):1752- 1764. doi: 10.1093/rheumatology/keaa016</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128:1728-1746. doi: 10.1161/CIRCRESAHA.121.319077</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128:1728-1746. doi: 10.1161/CIRCRESAHA.121.319077</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tanhapour M, Miri A, Vaisi-Raygani A. Synergism between apolipoprotein E Ɛ4 allele and paraoxonase (PON1) 55-M allele is associated with risk of systemic lupus erythematosus. Clin Rheumatol. 2018;37:971-977. doi: 10.1007/s10067-017-3859-3</mixed-citation><mixed-citation xml:lang="en">Tanhapour M, Miri A, Vaisi-Raygani A. Synergism between apolipoprotein E Ɛ4 allele and paraoxonase (PON1) 55-M allele is associated with risk of systemic lupus erythematosus. Clin Rheumatol. 2018;37:971-977. doi: 10.1007/s10067-017-3859-3</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev. 2020;2020:5245308. doi: 10.1155/2020/5245308</mixed-citation><mixed-citation xml:lang="en">Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev. 2020;2020:5245308. doi: 10.1155/2020/5245308</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ye Y, Wu T, Zhang T, Han J, Habazi D, Saxena R, et al. Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE. Clin Immunol. 2019;205:43-48. doi: 10.1016/j.clim.2019.05.004</mixed-citation><mixed-citation xml:lang="en">Ye Y, Wu T, Zhang T, Han J, Habazi D, Saxena R, et al. Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE. Clin Immunol. 2019;205:43-48. doi: 10.1016/j.clim.2019.05.004</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wirestam L, Jönsson F, Enocsson H, Svensson C, Weiner M, Wetterö J, et al. Limited association between antibodies to oxidized low-density lipoprotein and vascular affection in patients with established systemic lupus erythematosus. Int J Mol Sci. 2023;24(10):8987. doi: 10.3390/ijms24108987</mixed-citation><mixed-citation xml:lang="en">Wirestam L, Jönsson F, Enocsson H, Svensson C, Weiner M, Wetterö J, et al. Limited association between antibodies to oxidized low-density lipoprotein and vascular affection in patients with established systemic lupus erythematosus. Int J Mol Sci. 2023;24(10):8987. doi: 10.3390/ijms24108987</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Blachut D, Przywara-Chowaniec B, Tomasik A, Kukulski T, Morawiec B. Update of potential biomarkers in risk prediction and monitoring of atherosclerosis in systemic lupus erythematosus to prevent cardiovascular disease. Biomedicines. 2023;11(10):2814. doi: 10.3390/biomedicines11102814</mixed-citation><mixed-citation xml:lang="en">Blachut D, Przywara-Chowaniec B, Tomasik A, Kukulski T, Morawiec B. Update of potential biomarkers in risk prediction and monitoring of atherosclerosis in systemic lupus erythematosus to prevent cardiovascular disease. Biomedicines. 2023;11(10):2814. doi: 10.3390/biomedicines11102814</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost. 2018;16(3):418-428. doi: 10.1111/jth.13925</mixed-citation><mixed-citation xml:lang="en">Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost. 2018;16(3):418-428. doi: 10.1111/jth.13925</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Theofilis P, Sagris M, Antonopoulos AS, Oikonomou E, Tsioufis C, Tousoulis D. Inflammatory mediators of platelet activation: Focus on atherosclerosis and COVID-19. Int J Mol Sci. 2021;22(20):11170. doi: 10.3390/ijms222011170</mixed-citation><mixed-citation xml:lang="en">Theofilis P, Sagris M, Antonopoulos AS, Oikonomou E, Tsioufis C, Tousoulis D. Inflammatory mediators of platelet activation: Focus on atherosclerosis and COVID-19. Int J Mol Sci. 2021;22(20):11170. doi: 10.3390/ijms222011170</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131. doi: 10.1038/s41392-022-00955-7</mixed-citation><mixed-citation xml:lang="en">Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131. doi: 10.1038/s41392-022-00955-7</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gremmel T, Ay C, Riedl J, Kopp CW, Eichelberger B, Koppensteiner R, et al. Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thromb Haemost. 2016;115(3):615-621. doi: 10.1160/TH15-07-0598</mixed-citation><mixed-citation xml:lang="en">Gremmel T, Ay C, Riedl J, Kopp CW, Eichelberger B, Koppensteiner R, et al. Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thromb Haemost. 2016;115(3):615-621. doi: 10.1160/TH15-07-0598</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Badrnya S, Schrottmaier WC, Kral JB, Yaiw KC, Volf I, Schabbauer G, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler Thromb Vasc Biol. 2014;34(3):571-580. doi: 10.1161/ATVBAHA.113.302919</mixed-citation><mixed-citation xml:lang="en">Badrnya S, Schrottmaier WC, Kral JB, Yaiw KC, Volf I, Schabbauer G, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler Thromb Vasc Biol. 2014;34(3):571-580. doi: 10.1161/ATVBAHA.113.302919</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Reshetnyak T, Nurbaeva K. The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome. Int J Mol Sci. 2023;24(17):13581. doi: 10.3390/ijms241713581</mixed-citation><mixed-citation xml:lang="en">Reshetnyak T, Nurbaeva K. The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome. Int J Mol Sci. 2023;24(17):13581. doi: 10.3390/ijms241713581</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hally KE, La Flamme AC, Larsen PD, Harding SA. Platelet Tolllike receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction. Thromb Res. 2017;158:8-15. doi: 10.1016/j.thromres.2017.07.031</mixed-citation><mixed-citation xml:lang="en">Hally KE, La Flamme AC, Larsen PD, Harding SA. Platelet Tolllike receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction. Thromb Res. 2017;158:8-15. doi: 10.1016/j.thromres.2017.07.031</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131. doi: 10.1038/s41392-022-00955-7</mixed-citation><mixed-citation xml:lang="en">Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131. doi: 10.1038/s41392-022-00955-7</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Li B, Xia Y, Hu B. Infection and atherosclerosis: TLR-dependent pathways. Cell Mol Life Sci. 2020;77(14):2751-2769. doi: 10.1007/s00018-020-03453-7</mixed-citation><mixed-citation xml:lang="en">Li B, Xia Y, Hu B. Infection and atherosclerosis: TLR-dependent pathways. Cell Mol Life Sci. 2020;77(14):2751-2769. doi: 10.1007/s00018-020-03453-7</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Xue L, Liang YH, Gao YY, Wang XJ. Clinical study of Chlamydia pneumoniae infection in patients with coronary heart disease. BMC Cardiovasc Disord. 2019;19(1):110. doi: 10.1186/s12872-019-1099-y</mixed-citation><mixed-citation xml:lang="en">Xue L, Liang YH, Gao YY, Wang XJ. Clinical study of Chlamydia pneumoniae infection in patients with coronary heart disease. BMC Cardiovasc Disord. 2019;19(1):110. doi: 10.1186/s12872-019-1099-y</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Miao G, Zhao X, Wang B, Zhang L, Wang G, Zheng N, et al. TLR2/CXCR4 coassociation facilitates Chlamydia pneumoniae infection-induced atherosclerosis. Am J Physiol Heart Circ Physiol. 2020;318(6):H1420-H1435. doi: 10.1152/ajpheart.00011.2020</mixed-citation><mixed-citation xml:lang="en">Miao G, Zhao X, Wang B, Zhang L, Wang G, Zheng N, et al. TLR2/CXCR4 coassociation facilitates Chlamydia pneumoniae infection-induced atherosclerosis. Am J Physiol Heart Circ Physiol. 2020;318(6):H1420-H1435. doi: 10.1152/ajpheart.00011.2020</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов СА, Кухарчук ВВ, Карпов ЮА, Сергиенко ИВ, Драпкина ОМ, Семенова АЕ, и др. Субклинический атеросклероз как фактор риска сердечно-сосудистых осложнений. Кардиоваскулярная терапия и профилактика. 2012;11(3):82-86. doi: 10.15829/1728-8800-2012-3-82-86</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Kukharchuk VV, Karpov YuA, Sergienko IV, Drapkina OM, Semenova AE, et al. Subclinical atherosclerosis as a risk factor of cardiovascular events. Cardiovasc Ther Prev. 2012;11(3):82-86 (In Russ.). doi: 10.15829/1728-8800-2012-3-82-86</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Peng J, Dönnes P, Ardoin SP, Schanberg LE, Lewandowski L. Atherosclerosis progression in the APPLE trial can be predicted in young people with juvenile-onset systemic lupus erythematosus using a novel lipid metabolomic signature. Arthritis Rheumatol. 2024;76(3):455-468. doi: 10.1002/art.42722</mixed-citation><mixed-citation xml:lang="en">Peng J, Dönnes P, Ardoin SP, Schanberg LE, Lewandowski L. Atherosclerosis progression in the APPLE trial can be predicted in young people with juvenile-onset systemic lupus erythematosus using a novel lipid metabolomic signature. Arthritis Rheumatol. 2024;76(3):455-468. doi: 10.1002/art.42722</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Попкова ТВ, Панафидина TA, Новикова ДС, Александрова ЕН, Новиков АА, Новоселова ТЕ, и др. Значение маркеров воспаления в развитии атеросклероза и его осложнений при системной красной волчанке. Научно-практическая ревматология. 2013;51(6):646-653. doi: 10.14412/1995-4484-2013-646-53</mixed-citation><mixed-citation xml:lang="en">Popkova TV, Panafidina TA, Novikova DS, Aleksandrova EN, Novikov AA, Novoselova TE, et al. Role of inflammation markers in development of atherosclerosis and its compications in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(6): 646-653 (In Russ.). doi: 10.14412/1995-4484-2013-646-53</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira CB, Mariana JK. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol. 2022;44(3):309-324. doi: 10.1007/s00281-022-00922-y</mixed-citation><mixed-citation xml:lang="en">Oliveira CB, Mariana JK. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol. 2022;44(3):309-324. doi: 10.1007/s00281-022-00922-y</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
